12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

LabCorp sales and marketing update

LabCorp launched an enhanced version of HCV GenoSure NS3/4, a drug resistance test that screens for the Q80K polymorphism variant. The test provides resistance information for HCV drug Olysio simeprevir from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.), which has displayed reduced efficacy...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >